Can-Fite BioPharma Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Portfolio Pulse from Benzinga Newsdesk
Can-Fite BioPharma Ltd. has submitted an IND application to the FDA for a Phase IIb clinical trial of Namodenoson in MASH patients, aiming to address metabolic dysfunction-associated steatohepatitis (NASH).

April 03, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Can-Fite BioPharma Ltd. has submitted an IND application to the FDA for Namodenoson's Phase IIb trial in MASH patients.
Submitting an IND application to the FDA is a critical regulatory step for advancing clinical trials. Positive news about progressing to a Phase IIb trial could increase investor confidence in Can-Fite BioPharma's pipeline, potentially leading to a short-term positive impact on the stock price. The focus on NASH, a significant and growing market, underscores the potential value of Namodenoson if successful.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100